This is a routine director sale with no material signal. Monitor for any subsequent Form 4 filings to confirm execution, but no trading action warranted.
TVTX drugs
TVTX drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 15 $42.59entry
- T+1 · 6mo ago +0.70%α +0.77% · $42.89
- T+5 · 6mo ago +4.32%α +3.36% · $44.43
- T+20 · 5mo ago +26.32%α +24.20% · $53.80
- T+60 · 3mo ago +41.37%α +36.86% · $60.21
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Director Timothy Coughlin filed a Form 144 notice to sell 3,250 shares of Travere Therapeutics (TVTX) valued at approximately $141,183. The sale represents a small portion of his holdings and is routine for a director. No material impact expected.
Key Facts
- Director Timothy Coughlin filed Form 144 to sell 3,250 shares of TVTX
- Estimated sale value: $141,182.59
- Shares acquired via restricted stock awards on 11/18/2025
- Sale intended for 05/15/2026 on Nasdaq
- Broker: Wells Fargo Clearing Services
Financial Impact
Sale of 3,250 shares valued at ~$141K, representing a small fraction of director's holdings and <0.01% of TVTX's $4.1B market cap
Risk Factors
- Insider selling pattern could emerge if additional directors file similar notices
- Form 144 is intent to sell; sale may not be executed
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001376043-26-000004 |
| Document: 0001376043-26-000004-index.html | 0001376043-26-000004 |
| Document: 0001376043-26-000004.txt | 0001376043-26-000004 |
Track record
21 reports on TVTX
8 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +56.24% at T+60 after the Jun 2, 2026 report. 10 of 10 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $50.30 Now $49.70 −1.19% settles Nov 23
- Nov 5, 202611d ago SC 13G/A Neutral 2/10 Entry $48.87 to $51.56 Now $49.70 +1.70% ▲ +5.50% +2.21% vs SPY
- Nov 3, 202613d ago Institutional Cluster Bullish 4/10 Entry $49.41 to $51.99 Now $49.70 +0.59% ▲ +5.22% +5.81% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $49.41 to $51.99 Now $49.70 +0.59% ▲ +5.22% +5.81% vs SPY
- Sep 17, 20268w ago Insider Cluster Bearish 4/10 Entry $62.76 to $59.44 Now $49.70 +20.81% ▲ +5.29% +6.56% vs SPY
- Jul 9, 202618w ago 8-K Neutral 2/10 Entry $56.59 to $55.28 Now $49.70 −12.18% ▼ −2.31% −1.75% vs SPY
- Jun 16, 202621w ago Insider Cluster Neutral 2/10 Entry $54.14 to $57.69 Now $49.70 −8.20% ▲ +6.56% +7.60% vs SPY
- Jun 16, 202621w ago 8-K Neutral 2/10 Entry $54.14 to $57.69 Now $49.70 −8.20% ▲ +6.56% +7.60% vs SPY
- Jun 12, 202622w ago 144 Neutral 2/10 Entry $52.04 to $55.15 Now $49.70 −4.50% ▲ +5.98% +5.30% vs SPY
- Jun 2, 202623w ago 8-K Bullish 6/10 Entry $42.96 to $48.57 Now $49.70 +15.69% ▲ +13.06% +16.02% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers